S&P Futures
4,370.25-51.50(-1.16%)Dow Futures
33,976.00-486.00(-1.41%)Nasdaq Futures
15,175.00-151.00(-0.99%)Russell 2000 Futures
2,194.50-33.80(-1.52%)Crude Oil
70.70-1.27(-1.76%)Gold
1,757.20+5.80(+0.33%)
Reneo Pharmaceuticals, Inc. (RPHM)
- GlobeNewswire
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will be participating in five investor conferences during the month of September. Details for the upcoming conferences are as follows: Conference: Citi 16th Annual BioPharma ConferenceDate: September 8-10, 2021Form
- GlobeNewswire
Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results
First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathiesIRVINE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended June 30, 2021 and provided an update on its clinical programs. “The second quarter of 2021 was highly productive
- GlobeNewswire
Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study
IRVINE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the first patient has been dosed in the STRIDE study. The trial is designed to evaluate the efficacy and safety of REN001 for the treatment of patients with primary mitochondrial myopathies (PMM). STRIDE is a global, double-blin
